ZIM
NKTR icon

Zacks Investment Management’s Nektar Therapeutics NKTR Stock Holding History

Zacks Investment Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,404
Closed -$24.5K – 750
2025
Q1 		$24.5K Buy
+2,404
New +$31.4K ﹤0.01% 648
2018
Q1 		– Sell
-788
Closed -$706K – 585
2017
Q4 		$706K Buy
+788
New +$466K 0.02% 451
2016
Q4 		– Sell
-848
Closed -$219K – 700
2016
Q3 		$219K Buy
+848
New +$218K 0.01% 570

Other funds holding NKTR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Zacks Investment Management's NKTR Position: Q2 2025 in Review

Zacks Investment Management sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 2,404 shares — an estimated $24.5K sold.

Zacks Investment Management first reported a position in NKTR in Q3 2016 and held it in 3 quarters. The position peaked at $706K in Q4 2017. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

  • Zacks Investment Management reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Zacks Investment Management sold 2,404 Nektar Therapeutics shares in Q2 2025, an estimated $24.5K.
  • Zacks Investment Management first reported a position in Nektar Therapeutics in Q3 2016 and held it in 3 quarters.
  • Zacks Investment Management's Nektar Therapeutics position peaked at $706K in Q4 2017.
  • 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on Zacks Investment Management's 13F filing for Q2 2025, filed 12 Aug 2025.